Qiming Venture Partners’ Post

🚀 We are proud to announce our 𝗹𝗮𝘁𝗲𝘀𝘁 𝗰𝗼𝗹𝗹𝗮𝗯𝗼𝗿𝗮𝘁𝗶𝗼𝗻 with GlyTherix Ltd, providing 𝗚𝗠𝗣-𝗴𝗿𝗮𝗱𝗲 𝗻𝗼𝗻-𝗰𝗮𝗿𝗿𝗶𝗲𝗿-𝗮𝗱𝗱𝗲𝗱 𝗟𝘂𝘁𝗲𝘁𝗶𝘂𝗺-𝟭𝟳𝟳 𝗰𝗵𝗹𝗼𝗿𝗶𝗱𝗲 to support 𝘁𝗵𝗲𝗺 in their quest to develop 𝗻𝗼𝘃𝗲𝗹 𝘁𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀 for some of the most 𝗮𝗴𝗴𝗿𝗲𝘀𝘀𝗶𝘃𝗲 𝗮𝗻𝗱 𝗶𝗻𝘃𝗮𝘀𝗶𝘃𝗲 𝗰𝗮𝗻𝗰𝗲𝗿𝘀. 🔬 🌟 Our 𝗵𝗶𝗴𝗵-𝗽𝘂𝗿𝗶𝘁𝘆 𝗻.𝗰.𝗮. 𝗟𝘂-𝟭𝟳𝟳 will play a crucial role in GlyTherix's 𝗶𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝘃𝗲 𝗮𝗽𝗽𝗿𝗼𝗮𝗰𝗵, which combines Lu-177 with an antibody targeting 𝗚𝗹𝘆𝗽𝗶𝗰𝗮𝗻-𝟭—a protein found in aggressive tumors such as 𝗽𝗿𝗼𝘀𝘁𝗮𝘁𝗲, 𝗽𝗮𝗻𝗰𝗿𝗲𝗮𝘁𝗶𝗰, 𝗯𝗹𝗮𝗱𝗱𝗲𝗿, 𝗹𝘂𝗻𝗴, 𝗴𝗹𝗶𝗼𝗯𝗹𝗮𝘀𝘁𝗼𝗺𝗮, 𝗮𝗻𝗱 𝗼𝘃𝗮𝗿𝗶𝗮𝗻 𝗰𝗮𝗻𝗰𝗲𝗿𝘀. Eckert & Ziegler’s Lutetium-177 will play a central role in GlyTherix's clinical journey. 💬 “We are happy to collaborate with GlyTherix in their mission to develop 𝗰𝘂𝘁𝘁𝗶𝗻𝗴-𝗲𝗱𝗴𝗲 𝗿𝗮𝗱𝗶𝗼𝗽𝗵𝗮𝗿𝗺𝗮𝗰𝗲𝘂𝘁𝗶𝗰𝗮𝗹𝘀,” said Dr. Harald Hasselmann, CEO of Eckert & Ziegler SE, “Contributing to the success of such 𝗶𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝘃𝗲 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁𝘀 in clinical trials and beyond with our 𝗵𝗶𝗴𝗵-𝗾𝘂𝗮𝗹𝗶𝘁𝘆 𝗿𝗮𝗱𝗶𝗼𝗶𝘀𝗼𝘁𝗼𝗽𝗲𝘀, including Lutetium-177, is 𝗼𝘂𝗿 𝗱𝗶𝘀𝘁𝗶𝗻𝗰𝘁 𝗴𝗼𝗮𝗹.” Through our commitment to 𝘀𝘂𝗽𝗽𝗹𝘆 𝗰𝗵𝗮𝗶𝗻 𝗲𝘅𝗰𝗲𝗹𝗹𝗲𝗻𝗰𝗲 𝗮𝗻𝗱 𝗚𝗠𝗣 𝘀𝘁𝗮𝗻𝗱𝗮𝗿𝗱𝘀, Eckert & Ziegler aims to 𝗲𝗺𝗽𝗼𝘄𝗲𝗿 𝗴𝗿𝗼𝘂𝗻𝗱𝗯𝗿𝗲𝗮𝗸𝗶𝗻𝗴 𝗮𝗱𝘃𝗮𝗻𝗰𝗲𝘀 in radiopharmaceuticals, 𝗳𝘂𝗲𝗹𝗶𝗻𝗴 𝘁𝗵𝗲 𝗳𝘂𝘁𝘂𝗿𝗲 of 𝗽𝗿𝗲𝗰𝗶𝘀𝗶𝗼𝗻 𝗼𝗻𝗰𝗼𝗹𝗼𝗴𝘆. 💙 🔗 Read the 𝗳𝘂𝗹𝗹 𝗽𝗿𝗲𝘀𝘀 𝗿𝗲𝗹𝗲𝗮𝘀𝗲 and find out more ▶️ https://lnkd.in/eEpZC2dd #ContributingToSavingLives  #Radiopharmaceuticals #NuclearMedicine #PrecisionOncology #Lutetium177

💪What a month for cancer treatment breakthroughs and why I am sad! In September 2024, the FDA made remarkable advancements in oncology, including the approval of: Genentech (Roche) stands behind the approval of the subcutaneous formulation of atezolizumab (TECENTRIQ® (atezolizumab) providing a more convenient treatment option for multiple cancers. Novartis earned approval for ribociclib (KISQALI HCP ) in early-stage breast cancer, broadening treatment possibilities for patients at high risk of recurrence. Sanofi developed isatuximab (Sarclisa), which was approved for multiple myeloma. AstraZeneca continues to push the boundaries with Osimertinib (Osmigen) (Tagrisso), now approved for advanced non-small cell lung cancer (NSCLC). However with the rapid advancements in oncology, the urgency for technologies that can optimize patient-tailored treatments has never been greater. As new therapies emerge, ensuring that patients receive the most effective, personalized care is critical. Diagnostic tools that enable precision in treatment choices are not just a luxury—they are essential for improving outcomes and reducing unnecessary side effects. It makes me sad to see how vital ARTIDIS technology is for transforming patient care, yet impactful innovation takes time. Despite the urgency, we remain committed to delivering solutions that meet the highest standards. ARTIDIS is set to redefine personalized treatment, and we remain committed to making that future a reality, step by step. #Cancertreatment #ARTIDIS #Technology #Medtech #Future

Happy Friday all! Check out this open access Cell Trends in Cancer review by Herrera et al., "Bispecific antibodies: advancing precision oncology" and be sure to check out our growing portfolio of bispecifics & related tools: https://lnkd.in/gKeniYhr https://lnkd.in/gCbXy7a2 Highlights: Bispecific antibodies (bsAbs) offer a novel approach to anticancer therapy by targeting different antigens via a range of mechanisms of action. Manipulating bsAb structures allows generation of multiple formats to optimize molecular function for specific clinical contexts. Thus far, a total of seven bsAbs have received regulatory approval for use in hematological malignancies and four in select solid tumors, with notable clinical efficacy. The toxicities associated with the use of bsAbs need bespoke management strategies and expertise in clinical use. Understanding mechanisms of resistance to bsAbs is crucial to rational combination regimens or sequencing with other therapeutics to improve patient outcomes. #drugdiscovery #cancerresearch #antibodies #bispecifics #bites #immunotherapy #immunooncology #scientificresearch

The 2024 American Association for Cancer Research (AACR) Annual Meeting was held in San Diego, USA from April 5th to 10th. This conference is one of the largest cancer research meetings in the world and serves as a highly influential platform for the exchange of oncology research and clinical advances globally. At the meeting, Inventis Bio announced the latest results of the phase 2 clinical trial of garsorasib (D-1553) in patients with non-small cell lung cancer (NSCLC) harboring KRAS G12C mutation. In patients with locally advanced or metastatic NSCLC who have undergone prior treatment with anti-PD-(L)1 therapy and platinum-containing chemotherapy, garsorasib demonstrated an objective response rate (ORR) of 50%, a disease control rate (DCR) of 89%, a median duration of response (DOR) of 12.8 months, and a median progression-free survival (PFS) of 7.6 months. #APIs #Medical #Rawmaterials #Pharma #Pharmaceutical

Microbiome modulation is a 'patient-friendly' way to potentially boost responses to cancer immunotherapy. Will be following closely and looking forward to developments in the next few years

A major milestone as we can confirm that the first patient has been dosed in our international Phase 1b MELODY-1 trial of MB097, our precision microbiome co-therapy in advanced melanoma. Given as a co-therapy with MSD’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab), MB097 aims to enhance immune response for patients who haven't responded to existing immunotherapies - representing up to 50% of advanced melanoma cases. MELODY-1 is set to recruit up to 40 patients across the UK, France, Italy, and Spain, with initial data readouts expected by the end of 2025. MB097, an orally administered live biotherapeutic product, contains a defined consortium of commensal bacterial strains designed to enhance the efficacy of immune checkpoint inhibitors. With the potential to transform treatment for patients who are resistant to current therapies, we’re looking forward to seeing how MB097 can impact cancer care. 🔗 Read the press release: https://lnkd.in/e8Q5PzSE 🔬www.microbiotica.com #Biotech #Pharma #Innovation #Microbiome #ClincialTrials #CancerResearch #DrugDevelopment #Melanoma

🌟 PD-1 Non-small Cell Lung Cancer Market Size in the 7MM was ~USD 11,000 Million in 2023, is expected to show positive growth by 2034 🌟 Non-Small Cell Lung Cancer (#NSCLC) remains a formidable challenge in oncology, representing a significant proportion of global cancer cases. However, advancements in #immunooncology have redefined treatment paradigms, with #PD1Inhibitors emerging as game-changers in the therapeutic landscape. PD-1 inhibitors like #nivolumab and #pembrolizumab have demonstrated unprecedented efficacy in treating NSCLC by enhancing the immune system's ability to target cancer cells. These breakthroughs have not only improved survival rates. Leading PD-1 Non-small Cell Lung Cancer Companies are shown below:- 1. Regeneron Pharmaceuticals 2. Sanofi 3. Bavarian Nordic 4. Sichuan University 5. Chengdu MedGenCell Co. Ltd. 6. Merck Group 7. Dynavax Technologies Corporation 8. BeiGene 9. TESARO, Inc. Inc. 10. Bristol Myers Squibb and others. 💡 Stay informed. Stay competitive. Gain access to unparalleled market insights that could shape the future of NSCLC treatment. 🌐 Visit DelveInsight for the full report @ https://lnkd.in/e_6fzAWx Together, let’s transform challenges into opportunities in the fight against lung cancer! #LungCancer #PD1Inhibitors #NonSmallCellLungCancer #NSCLC #ImmunoOncology #PharmaTrends #HealthcareInsights #DelveInsight #MarketResearch

Exciting news from Agilent Technologies! The PD-L1 IHC 28-8 PharmDx test has achieved the prestigious Class C certification under the European Union's In Vitro Diagnostic Regulation. This certification positions it as a crucial companion diagnostic tool for guiding cancer treatment decisions, particularly for therapies incorporating anti-PD-1 antibodies. Specifically designed to detect the PD-L1 protein, this test serves as a vital biomarker to assess potential responses to various therapies, including those featuring Bristol Myers Squibb's Opdivo (nivolumab) and Opdualag (nivolumab and relatlimab). Learn more about this significant development at the provided link. #PrecisionMedicine #CancerTreatment #companiondiagnostics #Opdivo #Opdualag #BMS

Prostate Specific Surface Antigen: Wanted #Prostate cancer (#PC) is the second-most common cancer in men and the most frequently diagnosed non-cutaneous cancer in men, with increasing morbidity and mortality. PC was estimated to account for over 1,414,000 new cases and over 375,000 cancer-related deaths worldwide. #PSMA (Prostate-specific membrane antigen) is a transmembrane protein, overexpressed by prostate cancer cells and is accessible for binding anti-bodies or low-molecular-weight radioligands due to its extracellular portion. In this review, authors measures length, width, and depth of #PSMA and its utility as tangible diagnostic and therapeutic target. Variety of diagnostic and therapeutic modalities have been reviewed and summarized in the work. #PSMA-Targeted Radioligands, #Radionuclide-based therapy agents, #J591 antibody, #Radio-labeled low-weight molecules, #vipivotide tetraxetan (#Pluvicto®), beta and alpha-emitting therapeutics, #bispecific antibodies (#AMG-212, #AMG-160, #APVO442, #JNJ-081, #BAY2010112, #CC-1, #REGN5678), #ADC, and CAR T cells. Citation: Lena M. Unterrainer, Jeremie Calais, and Neil H. Bander (2024) Prostate-Specific Membrane Antigen: Gateway to Management of Advanced Prostate Cancer. Annual Review of Medicine, 75:49–66. DOI: 10.1146/annurev-med-081522-031439. Image from: sinobiological.com

🔍 Unveiling Insights: HER2-Positive Breast Cancer Market Analysis by DelveInsight Business Research LLP HER2-positive #breastcancer remains a significant concern in oncology, representing a subset of breast cancer cases with overexpression of the human epidermal growth factor receptor 2 (#HER2) protein. The HER2-positive breast cancer market is fueled by innovations in targeted therapies, including #monoclonalantibodies, antibody-drug conjugates (ADCs), and #tyrosinekinaseinhibitors (TKIs). The growing adoption of personalized medicine and combination regimens is reshaping treatment paradigms. The leading #HER2PositiveBreastCancerCompanies such as Byondis | Roche Ambrx | Zymeworks Inc. | Jazz Pharmaceuticals | Pfizer and others. Explore how groundbreaking innovations and strategic collaborations are driving progress in the #HER2positivebreastcancermarket. 👉 For an exclusive preview of the report, visit DelveInsight Business Research LLP's HER2-Positive Breast Cancer Market Report @ https://lnkd.in/dg5wXwAT #HER2PositiveBreastCancer #BreastCancerMarket #OncologyInnovation #HealthcareInsights #DelveInsight